SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-06-18
👔
MoonLake Immunotherapeutics
@MLTX_InsiderForm 4 Filing: Phillips Andrew John Acquires (Grant) shares of $MLTX
STOCK AWARD / GRANT
⚡ MATERIALITY: 1/10
corporate issuer
MoonLake Immunotherapeutics
Ticker: $MLTX
Transaction Value
N/A (Non-Open-Market)
Price/Share: $0.00 (Non-Open-Market)
transaction date
2026-06-17
Shares: 22,195
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Phillips Andrew John, holds the title of Director at MoonLake Immunotherapeutics.
On 2026-06-17, the insider transacted 22,195 shares.This transaction is a non-open-market event (such as a stock grant or option exercise) with a reported price per share of $0.00.
Executive Summary Summary
Phillips Andrew John (Director) was granted $0 of $MLTX
Post-Transaction Position: 22,195 shares
SEC Accession No: 0001213900-26-070258 (CIK: 1921956)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.